Recent developments in adjunct therapies for type 1 diabetes.
Expert opinion on investigational drugs(2022)
摘要
As evidence emerges for cardiorenal protection by SGLT2is and GLP-1RAs in T2D, it has become increasingly important to know whether people with T1D can also benefit. Here, we review recent trials of adjunct agents in T1D and discuss the efficacy and safety of these agents (alone and in combination) in an era in which continuous glucose monitoring is becoming standard of care.
更多查看译文
关键词
Adjunct therapy,GLP-1 receptor agonists,SGLT-2 inhibitors,type 1 diabetes
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要